Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolemia

Archives of Cardiovascular Diseases

Volumn 103, Issue 1, 2010, Pages 26-32

  Kostakou, Peggy ^a   Kolovou, Genovefa ^a   Anagnostopoulou, Katherine ^a   Theodoridis, Theodor ^b   Galea, Vassiliki ^b   Mihas, Constantinos ^c   Christopoulou Cokkinou, Vassiliki ^b   Cokkinos, Dennis V ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c General Hospital of Kimi   (Greece)

Author keywords

C reactive protein; Ezetimibe; Lipid; Simvastatin; Tissue factor; Von Willebrand

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; C REACTIVE PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; THROMBOPLASTIN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PLEIOTROPY;

EID: 77249111659     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2009.10.003     Document Type: Article

References (47)

1. Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother 2004;5:2583-96.
2. Miller M, Dobs A, Yuan Z, et al. The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study. Curr Med Res Opin 2006;22:343-50.
3. Davidson MH. A look to the future: new treatment guidelines and a perspective on statins. Am J Med 2002;112(Suppl 8A):34S-41S.
4. Kolovou GD, Anagnostopoulou KK, Salpea KD, et al. The effect of statins on postprandial lipemia. Curr Drug Targets 2007;8:551-60.
5. Kolovou GD, Katerina A, Ioannis V, et al. Simvastatin: two decades in a circle. Cardiovasc Ther 2008;26:166-78.
6. Kolovou GD, Mikhailidis DP, Daskalova DC, et al. The effect of co-administration of simvastatin and alcohol in rats. In Vivo 2003;17:523-7.
7. Kolovou GD, Salpea KD, Mihas C, et al. Comparison of simvastatin and nicotinic acid administration in alcohol-treated Wistar rats. Hellenic J Cardiol 2008;49:79-85.
8. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res 2006;47:1339-51.
9. Manuel DG, Kwong K, Tanuseputro P, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ 2006;332:1419.
10. Nolting PR, de Groot E, Zwinderman AH, et al. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 2003;163:1837-41.
11. Kolovou G. The treatment of coronary heart disease: an update. Part 3: Statins beyond cholesterol lowering. Curr Med Res Opin 2001;17:34-7.
12. Horiuchi N, Maeda T. Statins and bone metabolism. Oral Dis 2006;12:85-101.
13. Wolozin B, Manger J, Bryant R, et al. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:63-70.
14. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
16. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004;109:1127-33.
17. Al-Shaer MH, Choueiri NE, Suleiman ES. The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia. Lipids Health Dis 2004;3:22.
18. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-63.
19. Fleck RA, Rao LV, Rapaport SI, et al. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990;59:421-37.
20. Wilcox JN, Smith KM, Schwartz SM, et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 1989;86:2839-43.
21. Rickles FR, Shoji M, Abe K. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer, Int J Hematol 2001;73:145-50.
22. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006;113:722-31.
23. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res 2007;120(Suppl 1):S5-9.
24. Blann AD. Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? Blood Coagul Fibrinolysis 2000;11:623-30.
25. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 1998;80:334-7.
26. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
27. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005;3:1618-27.
28. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
30. Quinaglia e Silva JC, Munhoz DB, Morato TN, et al. Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction. Am J Cardiol 2009;103:461-3.
31. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
32. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006;97:33A-41A.
33. Nemerson Y, Bach R. Tissue factor revisited. Prog Hemost Thromb 1982;6:237-61.
34. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995;91:619-22.
35. Soejima H, Ogawa H, Yasue H, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999;99:2908-13.
36. Gralnick HR, Williams SB, McKeown LP, et al. Platelet von Willebrand factor. Mayo Clin Proc 1991;66:634-40.
37. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.
38. Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002;105:1756-9.
39. Bea F, Blessing E, Shelley MI, et al. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis 2003;167:187-94.
40. Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol- associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006;10:851-66.
41. Maki-Petaja KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007;50:852-8.
42. Fichtischerer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006;27:1182-90.
43. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43.
44. Lee KW, Blann AD, Lip GY. Inter-relationships of indices of endothelial damage/dysfunction [circulating endothelial cells, von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute coronary syndromes, Int J Cardiol 2006;111:302-8.
45. Lwaleed BA, Vayro S, Racusen LC, et al. Tissue factor expression by a human kidney proximal tubular cell line in vitro: a model relevant to urinary tissue factor secretion in disease? J Clin Pathol 2007;60:762-7.
46. Szotowski B, Antoniak S, Goldin-Lang P, et al. Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells. Cardiovasc Res 2007;73:806-12.
47. Chan A, Jayasuriya K, Berry L, et al. Volutrauma activates the clotting cascade in the newborn but not adult rat. Am J Physiol Lung Cell Mol Physiol 2006;290. L754-L60.